Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hirudoid + yellow light plus oral tofacitinib vs oral tofacitinib alone for erythematotelangiectatic rosacea
ChiCTR2500111274Phase 4Not yet recruiting
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-blind trial of tofacitinib in rosacea (2 arms), sponsored by The Fourth Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: IGA treatment success at Week 12. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
03
Conditions
rosacea
Beyond the preview
Go deeper on ChiCTR2500111274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111274.